| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| LJL Biosystems, Inc. |
| 404 Tasman Drive, Sunnyvale, CA 94089 * (408) 541-8787 |
| LJL is developing and marketing proprietary technologies and products to accelerate and enhance the drug discovery process. |
| Manager | Tier | Phone |
| Nationsbanc Montgomery Securities, Inc. | Lead Manager | (415) 627-2100 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| Volpe Brown Whelan & Company | Co-manager | (415) 274-4463 |
| NASNTL: | LJLB | Manufacturing: | SIC 3826 | |
| Type of Shares: | Common Shares | Filing Date: | 12/31/97 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 3/12/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $8.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.49 | |
| Offering Amount: | $15,000,000 | Selling: | $0.25 | |
| Expenses: | $700,000 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 10,622,003 |
| Issuer's Law Firm: | Venture Law Group |
| Bank's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Auditor: | Price Waterhouse |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/96 | 9/30/97 | 9/30/96 | 9/30/97 | ||
| Revenue: | $9.29 | $4.88 | $6.72 | Assets: | $7.85 |
| Net Income: | $0.16 | -$0.78 | $0.21 | Curr Assets: | $7.48 |
| EPS: | $0.02 | -$0.09 | Liabilities: | $1.43 | |
| Prior EPS: | Curr Liab: | $1.38 | |||
| Cash Flow/Oper: | -$0.01 | -$1.36 | $2.89 | Equity: | $6.42 |
| Cash Flow/Fin: | -$0.50 | $7.62 | -$0.33 | Cash: | $7.12 |
| Cash Flow/Inv: | -$0.09 | -$0.31 | -$0.04 | Working Cap: | $6.10 |
| Competition |
| The market for HTS products is highly competitive. The Company expects that competition will increase significantly as more biotechnology and pharmaceutical companies adopt high throughput screening instruments as a drug discovery tool and as new companies enter the market with advanced technologies. The Company will compete in many areas, including high throughput screening instruments, assay development and reagent sales. The Company competes with companies which directly market HTS products. In addition, pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other research organizations are conducting research and developing products in various areas which compete with the Company's technology platform, either on their own or in collaboration with others. Many of these competitors have greater financial, operational and sales and marketing resources, and more experience in research and development, than the Company. Further, certain companies offer screening services on a contract or collaborative basis, and these services could eliminate the need for a potential customer to purchase the Company's products. The Company's technological approaches may be rendered obsolete or uneconomical by advances in existing technological approaches or the development of different approaches by one or more of the Company's current or future competitors. |
| Business Plan |
| In the second half of 1996, the Company implemented a new strategic business model to develop products for the HTS market. In connection with this change in strategy, the Company shifted its focus from developing and manufacturing clinical diagnostic and research products on an original equipment manufacturing ("OEM") basis to developing, manufacturing and marketing products for the HTS market. As a result, the Company's historical operating and financial performance is not indicative of future financial and business results. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund research and development of future products, acquisitions and for general corporate purposes. |